Company news

Agios Pharmaceuticals, Inc. news in 2024

Agios Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease

December 17, 2024

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

December 7, 2024

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

November 4, 2024

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

October 30, 2024

Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

October 22, 2024

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

October 16, 2024

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)

September 10, 2024

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

September 4, 2024

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

August 5, 2024

Agios Reports Business Highlights and Second Quarter 2024 Financial Results

July 31, 2024

Agios Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

July 31, 2024

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

July 17, 2024

Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

June 14, 2024

Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8: 40 am ET

June 5, 2024

Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

June 2, 2024

Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 29, 2024

Agios Announces $905 Million Purchase Agreement for Vorasidenib Royalty

May 27, 2024

Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress

May 13, 2024

Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024

May 5, 2024

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024

May 2, 2024

Agios Reports Business Highlights and First Quarter 2024 Financial Results

May 1, 2024

Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024

April 17, 2024

Agios Publishes 2024 Environmental, Social and Governance (ESG) Report

April 8, 2024

Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024

March 4, 2024

Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024

February 21, 2024

Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

February 14, 2024

Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024

February 1, 2024

Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

January 7, 2024

Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia

January 2, 2024

Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

January 1, 2024

Calls in 2024

Decks in 2024